Susan has embraced the technical, business and marketing side of life sciences since her first role as a Roche ChE Process Engineer. In 2004, she was named Commercial Director for Foster Wheeler, a pharma engineering firm, and traveled the world's leading pharma sites. She then launched an award winning life sciences marketing comms firm, McDay, later sold to CG Life and remained as EVP, until she took over as CEO of Phylloceuticals in 2024.

The world expert in Lemna, the plant being used by Phylloceuticals to make our biosimilars. Dr. Dickey was previously the VP of Research and Technology at Biolex Therapeutics, where she oversaw the development of the Lemna plant-based core technology, including genetic engineering, bioanalytics, product development, and design of the aseptic biomanufacturing format.

She was later VP of R & D/Gen'l Mgr for Synthon Pharmaceuticals.

Dr. Brown has extensive experience in drug development and biomanufacturing. He is a professor in the Department of Clinical Sciences at Colorado State University where he served as Head of the Global Health and Health Disparities Section and as a Molecular Oncologist in the Cancer Center. He has 150+ publications and keynotes in the areas of colorectal, hepatocellular, breast, and lung carcinomas and leukemia/infectious diseases.

Mitch Nachtigall's diverse background encompasses biotechnology, entrepreneurship, and military leadership. Mitch has served as Lieutenant Colonel and Executive Officer to the Adjutant General in the United States military, COO at CellField Technologies which specializes in modular cell culture platforms aimed at revolutionizing drug development for osteoarthritis and rheumatoid arthritis treatments.

Lu holds a BSME and an MBA, obtained through a joint degree program between Columbia Business School and London Business School.
In the early stages of his career, Lu spent a decade at EY, where he worked on financial systems and business transformation projects for Fortune 500 companies. Lu has spent the last 15 years in executive roles for investors, including family offices and hedge funds, w/ COO and CFO positions in early-stage companies.

With over 45 years in biotech manufacturing, Bill's contacts inside the capital operations and manufacturing world are unmatched. His deep knowledge of mammalian cell culture facilities/scale-up allow him to judiciously conduct conversations w/ Big Pharma to consider plant-made manufacturing, in an extremely credible way. An original founder @ Biokinetics, one of the first biotech engineering firms in the industry, and CEO of Foster W BioK.